EP4590721A4 - Molekular gepfropftes immunglobulin mit mehreren funktionen oder bindungsspezifitäten - Google Patents

Molekular gepfropftes immunglobulin mit mehreren funktionen oder bindungsspezifitäten

Info

Publication number
EP4590721A4
EP4590721A4 EP23869178.6A EP23869178A EP4590721A4 EP 4590721 A4 EP4590721 A4 EP 4590721A4 EP 23869178 A EP23869178 A EP 23869178A EP 4590721 A4 EP4590721 A4 EP 4590721A4
Authority
EP
European Patent Office
Prior art keywords
binding properties
multiple functions
molecularly
grafted immunoglobulin
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23869178.6A
Other languages
English (en)
French (fr)
Other versions
EP4590721A2 (de
Inventor
Donglin Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Frontaim Biomedicines Inc
Original Assignee
Frontaim Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frontaim Biomedicines Inc filed Critical Frontaim Biomedicines Inc
Publication of EP4590721A2 publication Critical patent/EP4590721A2/de
Publication of EP4590721A4 publication Critical patent/EP4590721A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
EP23869178.6A 2022-09-23 2023-09-21 Molekular gepfropftes immunglobulin mit mehreren funktionen oder bindungsspezifitäten Pending EP4590721A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263376836P 2022-09-23 2022-09-23
PCT/US2023/074758 WO2024064804A2 (en) 2022-09-23 2023-09-21 Molecularly grafted immunoglobulin with multiple functions or binding specificities

Publications (2)

Publication Number Publication Date
EP4590721A2 EP4590721A2 (de) 2025-07-30
EP4590721A4 true EP4590721A4 (de) 2026-03-25

Family

ID=90455259

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23869178.6A Pending EP4590721A4 (de) 2022-09-23 2023-09-21 Molekular gepfropftes immunglobulin mit mehreren funktionen oder bindungsspezifitäten

Country Status (3)

Country Link
EP (1) EP4590721A4 (de)
CN (1) CN119816521A (de)
WO (1) WO2024064804A2 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022225A1 (en) * 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy
US20160129086A1 (en) * 2008-04-10 2016-05-12 Ibc Pharmaceuticals, Inc. Interferon lambda-antibody complexes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104363919A (zh) * 2012-06-01 2015-02-18 Ibc药品公司 具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
WO2023056240A2 (en) * 2021-09-28 2023-04-06 Frontaim Biomedicines, Inc. Multiple formats of molecular complexes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160129086A1 (en) * 2008-04-10 2016-05-12 Ibc Pharmaceuticals, Inc. Interferon lambda-antibody complexes
WO2010022225A1 (en) * 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy

Also Published As

Publication number Publication date
CN119816521A (zh) 2025-04-11
EP4590721A2 (de) 2025-07-30
WO2024064804A2 (en) 2024-03-28
WO2024064804A3 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
GB2595299B (en) Modified immunoglobulin FC regions
SI3720279T1 (sl) Miši, ki imajo spremenjeno lahko verigo imunoglobulina lambda in njihova uporaba
MA43773A (fr) Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
MA44091A (fr) Animaux non humains présentant un locus de chaîne légère d'immunoglobuline lambda modifié
IL284926A (en) Cd3-specific binding molecules
EP3912935C0 (de) Zweischichtiger linearer sortierer
EP3708667A4 (de) Immunoglobulinbindende proteine
EP4397106A4 (de) Duplexsignalisierung mit kreuzteilung
EP4200431A4 (de) Hypersialyliertes immunglobulin
EP4001361A4 (de) Polyesterharzmischung
EP3954918A4 (de) Kupplung mit umgekehrter eingangsblockierung
EP3925999A4 (de) Extrusionsformbares polyester-copolymer
PL3782361T3 (pl) Przestrzennie zmienna transformacja z transformacją typu adaptacyjnego
EP4393154A4 (de) Intrablockkopie mit adaptivem lokalem referenzbereich
EP4034145A4 (de) Nützliche bakterien und sekretorisches immunoglobulin a
EP4590721A4 (de) Molekular gepfropftes immunglobulin mit mehreren funktionen oder bindungsspezifitäten
EP4035079A4 (de) Umgedrehtes verstärkungslernen
EP4419565A4 (de) Biosynthetische biparatopische oder bispezifische bindungsmoleküle mit verbesserten effektorfunktionen
EP4218360C0 (de) Heizelement mit erhöhtem widerstand
EP4117576A4 (de) Mehrschichtiges gefässtransplantat
EP4460880A4 (de) Variable buchse mit vorgespannter rampenanordnung
EP4487314A4 (de) Adaptives lernen in einem ökosystem mit unterschiedlichem lernen
EP4386034A4 (de) Vernetztes polyesterharz
EP4118020A4 (de) Klammerloser binder mit erhöhter bindekraft
EP3936568A4 (de) Thermoplastische polyesterharzzusammensetzung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250306

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20260223

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 19/00 20060101AFI20260218BHEP

Ipc: C07K 16/30 20060101ALI20260218BHEP

Ipc: C07K 16/28 20060101ALI20260218BHEP

Ipc: C07K 16/32 20060101ALI20260218BHEP

Ipc: C07K 16/46 20060101ALI20260218BHEP

Ipc: A61K 39/395 20060101ALI20260218BHEP

Ipc: A61P 35/00 20060101ALI20260218BHEP